pSivida Corp. (PSDV) ,,,,, un GIOIELLO !!!
- Creatore Discussione acqua+
- Data di Inizio
DickSIM
Prima o poi....ci becco!
Io pure......e parecchio sotto i 3 dollari...!!!
a zi?
e quando le hai prese parecchie sotto i 3$........ il 2 ottobre......... 
sui minimi a 2.97$......o risalgono ancora ad Agosto? 
acqua+
ONDA NITRICA
a zi?
beh ,,, in effetti ,,, e visti i volumi
DickSIM
Prima o poi....ci becco!
pSivida Announces Completion of BrachySil Dose Ranging Study in Pancreatic Cancer
Wed Oct 21, 2009 9:00am EDT Email | Print | Share | Reprints | Single Page [-] Text [+]
WATERTOWN, Mass.--(Business Wire)--
pSivida Corp. (NASDAQ
SDV)(ASXVA)(FFV3), a leading drug delivery companytoday announced the completion of a second pancreatic clinical trial of
BrachySil (P32 BioSilicon), a potential new brachytherapy treatment for
inoperable pancreatic cancer. Six patients were studied at two centers in the UK
(Guy`s and St Thomas` NHS Foundation Trust and University Hospital, Birmingham).
The study was conducted to determine the safety of escalating radiation doses of
the BrachySil device and to determine an optimum dosing level. Tumor response
was also measured as a secondary end point.
The study escalated the absorbed targeted radiation dose by four-fold from the
previous study to 400 Gy (Gy or Gray is a unit of absorbed radiation dose due to
ionizing radiation). No device related serious adverse events were experienced
at the elevated levels and independent dosimetry experts have concluded from the
data that 400 Gy is the optimum dose.
The previous safety study presented last year at the American Society of
Clinical Oncology-GI showed that BrachySil in combination with standard
chemotherapy (gemcitabine), was well tolerated with no clinically significant
adverse events related to the device. Data in the first study showed disease
control in 82% of patients. BrachySil is implanted directly into the tumor and
was found to be easily deliverable by endoscopic ultrasound.
"BrachySil has once again produced encouraging clinical results with 100% of
patients experiencing stabilization in tumor growth," said Dr. Paul Ashton,
President and CEO of pSivida Corp. "We are very encouraged by the results of
both this dose ranging study and the prior safety study."
BrachySil is a novel oncology product which comprises a combination of
BioSilicon (a proprietary porous silicon) and the isotope 32Phosphorus, a proven
anti-cancer therapeutic. It is hoped this product will provide oncologists with
an effective and user-friendly new treatment for this disease which has a high
unmet clinical need.
Pancreatic cancer is the fourth most frequent cause of cancer death in the
United States, and at least 80% of patients present with inoperable locally
advanced or metastatic disease. The median survival for these patients following
diagnosis is typically less than six months with standard chemotherapy.
Accordingly, there is significant clinical and market demand for effective
therapies.
guly
Forumer storico
beh ,,, in effetti ,,, e visti i volumi
certo visti i volumi ieri di polli ne hanno acchiappati parecchi.un po' come su HGSI
DickSIM
Prima o poi....ci becco!
guly
Forumer storico
e pensa che il bello deve ancora venire....
difatti lo vedo pure oggi puzza di pollame.e pure con le news positive.pensa un po'che smacco per i polli.botte e carcerati
Netzach
Forumer storico
Orari mercati americani e mercato Forex
Da lunedì 26 a venerdì 30 ottobre
Mercato Azionario (Nyse, Nasdaq e Amex)
Apertura ore 14:30 - Chiusura ore 21:00
Mercato Derivati CME
Futures su Indici - chiusura ore 21:15
- chiusura intraday ore 20:30 Futures su Valute - chiusura ore 22:00 Futures su Commodities - chiusura ore 22:15
Da lunedì 26 a venerdì 30 ottobre
Mercato Azionario (Nyse, Nasdaq e Amex)
Apertura ore 14:30 - Chiusura ore 21:00
Mercato Derivati CME
Futures su Indici - chiusura ore 21:15
- chiusura intraday ore 20:30 Futures su Valute - chiusura ore 22:00 Futures su Commodities - chiusura ore 22:15
Similar threads
